###begin article-title 0
###xml 7 9 7 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 168 172 <span type="species:ncbi:10090">mice</span>
Kinin B2 receptor regulates chemokines CCL2 and CCL5 expression and modulates leukocyte recruitment and pathology in experimental autoimmune encephalomyelitis (EAE) in mice
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 102 104 102 104 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 109 110 109 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 551 553 551 553 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 747 752 747 752 <sub xmlns:xlink="http://www.w3.org/1999/xlink">35&#8211;55</sub>
###xml 768 772 <span type="species:ncbi:10090">mice</span>
Kinins are important mediators of inflammation and act through stimulation of two receptor subtypes, B1 and B2. Leukocyte infiltration contributes to the pathogenesis of autoimmune inflammation in the central nervous system (CNS), occurring not only in multiple sclerosis (MS) but also in experimental autoimmune encephalomyelitis (EAE). We have previously shown that the chemokines CCL2 and CCL5 play an important role in the adhesion of leukocytes to the brain microcirculation in EAE. The aim of the present study was to evaluate the relevance of B2 receptors to leukocyte-endothelium interactions in the cerebral microcirculation, and its participation in CNS inflammation in the experimental model of myelin-oligodendrocyte-glycoprotein (MOG)35-55-induced EAE in mice.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 134 135 134 135 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 135 138 135 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 161 166 161 166 <sub xmlns:xlink="http://www.w3.org/1999/xlink">35&#8211;55</sub>
###xml 275 276 275 276 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 276 280 276 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 140 144 <span type="species:ncbi:10090">mice</span>
###xml 291 295 <span type="species:ncbi:10090">mice</span>
In order to evaluate the role of B2 receptor in the cerebral microvasculature we used wild-type (WT) and kinin B2 receptor knockout (B2-/-) mice subjected to MOG35-55-induced EAE. Intravital microscopy was used to investigate leukocyte recruitment on pial matter vessels in B2-/- and WT EAE mice. Histological documentation of inflammatory infiltrates in brain and spinal cords was correlated with intravital findings. The expression of CCL5 and CCL2 in cerebral tissue was assessed by ELISA.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 48 49 48 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 49 53 49 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 302 303 302 303 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 303 307 303 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 53 57 <span type="species:ncbi:10090">mice</span>
###xml 89 93 <span type="species:ncbi:10090">mice</span>
###xml 307 311 <span type="species:ncbi:10090">mice</span>
Clinical parameters of disease were reduced in B2-/- mice in comparison to wild type EAE mice. At day 14 after EAE induction, there was a significant decrease in the number of adherent leukocytes, a reduction of cerebral CCL5 and CCL2 expressions, and smaller inflammatory and degenerative changes in B2-/- mice when compared to WT.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 26 28 26 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 98 100 98 100 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 175 177 175 177 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
Our results suggest that B2 receptors have two major effects in the control of EAE severity: (i) B2 regulates the expression of chemokines, including CCL2 and CCL5, and (ii) B2 modulates leukocyte recruitment and inflammatory lesions in the CNS.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 427 428 427 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 429 430 429 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 571 573 571 573 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 578 579 578 579 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 586 588 586 588 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 718 719 718 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 720 721 720 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 729 731 729 731 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 891 892 891 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 893 894 893 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1001 1002 1001 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
Bradykinin (BK) and its biologically active metabolites are the functional components of the kallikrein-kinin system. Kinins elicit a wide range of physiological effects including relaxation of vascular smooth muscle in arteries and arterioles, expression of adhesion molecules, leukocyte infiltration, formation of interendothelial gaps and protein extravasation from post-capillary venules, and pain transmission mechanisms [1,2]. The actions of kinins are mediated through stimulation of two subtypes of seven-transmembrane-domain G-protein-coupled receptors, namely B1 and B2. The B2 receptor is constitutively expressed in various cell types, including endothelial cells, nerve fibers, leukocytes and mast cells [3,4]. The B1 receptor is generally expressed at low levels under normal conditions but is up-regulated by cytokines in stressful situations, such as shock and inflammation [5-7]. Most of the physiological actions of kinins are believed to be mediated by stimulation of B2 receptors [8].
###end p 11
###begin p 12
###xml 333 334 333 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 465 467 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 150 155 <span type="species:ncbi:9606">human</span>
Experimental autoimmune encephalomyelitis (EAE) is an inflammatory disease of the CNS mediated by CD4+ Th1 cells that serves as experimental model of human multiple sclerosis (MS). A pathological hallmark of MS is infiltration of immune cells across the blood-brain barrier into the CNS causing myelin destruction and axonal injury [9]. It is thought that inappropriate leukocyte recruitment and activation in the brain results in disease symptoms and progression [10]. Thus, reduction of the migration of immune cells into the CNS is a relevant novel therapeutic strategy for the treatment of MS.
###end p 12
###begin p 13
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 423 424 423 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 834 836 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 972 974 972 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 975 977 975 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 453 459 <span type="species:ncbi:10090">murine</span>
###xml 524 535 <span type="species:ncbi:10141">guinea pigs</span>
###xml 966 970 <span type="species:ncbi:10090">mice</span>
Although the potential role of the kinin system on leukocyte entry into the CNS in MS remains unclear, it has been shown that BK can interfere with the mechanism of leukocyte recruitment in various tissues [11]. BK may enhance the expression of adhesion molecules on endothelium cells [12]. BK antagonists reduce leukocyte-endothelium interactions after diverse inflammatory conditions, including global cerebral ischemia [4], leukocyte infiltration in murine mesenteric post-capillary venules [13] and lung inflammation in guinea pigs [14]. BK could potentially modify leukocyte recruitment by production of chemoattractant molecules, such as chemokines. For example, treatment with bradykinin receptor antagonists has been shown to reduce production of chemokines, including KC and MCP-1, after intestinal ischemia and reperfusion [15]. Several studies, have clearly demonstrated the relevance of chemokines for the recruitment of leukocytes into the brain of EAE mice [16-18].
###end p 13
###begin p 14
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 188 190 188 190 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 195 197 195 197 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 361 362 361 362 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 570 575 570 575 <sub xmlns:xlink="http://www.w3.org/1999/xlink">35&#8211;55</sub>
###xml 373 377 <span type="species:ncbi:10090">mice</span>
Cross talk between cytokines and kinin receptors has been extensively investigated over the last several years [19-21]. Studies have demonstrated that pro-inflammatory cytokines regulate B1 and B2 receptor expression [11,22,23] and, conversely, blockade of kinins receptors modifies expression of cytokines and chemokines [24,25]. In the present work, we used B2-deficient mice to assess the potential contribution of kinin receptors for the clinical course of disease, leukocyte recruitment, and modulation of chemokines expression in the CNS after EAE induction by MOG35-55.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Animals
###end title 16
###begin p 17
###xml 6 8 6 8 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 19 20 19 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 20 23 20 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 25 29 <span type="species:ncbi:10090">mice</span>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
Mice B2 knockout (B2-/-) mice were generated as previously described [24]. Knockout female C57BL/6 X sv129 mice (9-11 wks) and their wild-type (WT) littermate controls were housed under standard conditions and had free access to commercial chow and water. All procedures described in this study had prior approval from the local Ethics Committee that governs animal care and use in research.
###end p 17
###begin title 18
EAE induction
###end title 18
###begin p 19
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 2 6 2 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 111 117 110 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink">35&#8211;55 </sub>
###xml 277 304 276 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mycobacterium tuberculosis </italic>
###xml 793 795 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 881 883 880 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
###xml 239 242 <span type="species:ncbi:31658">CFA</span>
###xml 277 303 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
###xml 802 806 <span type="species:ncbi:10090">mice</span>
B2-/- and WT mice were immunized subcutaneously at the base of the tail with an emulsion containing 100 mug MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK; (Dept Biophysics, Escola Paulista de Medicina, SP, Brazil) in Freund's complete adjuvant (CFA, Sigma) supplemented with 4 mg/mL Mycobacterium tuberculosis H37RA (Difco Laboratories). Pertussis toxin (Sigma), was injected (300 ng/animal, i.p.), on the day of immunization and 48 h later. Animals were monitored daily and neurological impairment was quantified on an arbitrary clinical scale and presented as mean clinical disease severity. Scores were: 0 = no clinical signs, 1 = tail paralysis (or loss of tail tone), 2 = tail paralysis and hind-limb weakness, 3 = hind-limb paralysis, 4 = complete hind-limb paralysis and front limb weakness [26]. The mice were weighed pre- and 14 days post-immunization, the peak of the disease [18]. "Sham animals" refers to WT animals without EAE induction.
###end p 19
###begin title 20
###xml 25 30 <span type="species:ncbi:10090">mouse</span>
Intravital microscopy in mouse brain
###end title 20
###begin p 21
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 713 715 707 709 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 725 727 719 721 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 738 740 732 734 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 111 115 <span type="species:ncbi:10090">mice</span>
###xml 349 354 <span type="species:ncbi:9568">drill</span>
###xml 475 480 <span type="species:ncbi:10090">mouse</span>
Intravital microscopy of cerebral microvasculature was performed as previously described [18,27]. Briefly, the mice were anaesthetized by intraperitoneal injection of a mixture containing ketamine (150 mg/kg) and xylazine (10 mg/kg). The tail vein was cannulated for administration of fluorescent dyes. A craniotomy was performed using a high-speed drill (Dremel, USA) and the dura matter was removed to expose the underlying pial vasculature. Throughout the experiment, the mouse was maintained at 37degreesC with a heating pad (Fine Science Tools Inc., Canada) and the exposed brain was continuously superfused with artificial cerebrospinal fluid buffer at pH 7.4, containing in mmol/L: NaCl 132, KCl 2.95, CaCl2 1.71, MgCl2 0.64, NaHCO3 24.6, dextrose 3.71 and urea 6.7, at 37degreesC.
###end p 21
###begin p 22
To assess leukocyte-endothelium interactions, leukocytes were fluorescently labeled by administration of rhodamine 6G (i.v., 0.5 mg/kg body weight) and observed using a microscope (Olympus B201, X20 objective lens, corresponding a 100 mum of area) outfitted with a fluorescent light source (epi-illumination at 510-560 nm, using a 590 nm emission filter). A silicon-intensified camera (Optronics Engineering DEI-470) mounted on the microscope projected the image onto a monitor (Olympus). Rolling leukocytes were defined as the number of white cells moving at a velocity lesser than that of erythrocytes cells. Leukocytes were considered adherent to the venular endothelium if they remained stationary for 30 seconds or longer.
###end p 22
###begin title 23
Histopathology
###end title 23
###begin p 24
Brains, cerebellum and the spinal cords were removed just after intravital microscopy. Transverse slices of brain, spinal cord and cerebellum were fixed by immersion in 10% formalin and processed for paraffin embedding. The sections (6.0 mum) were stained with H&E and examined in an Olympus BX51 microscope. Documentation was performed by a coupled digital camera and imaging capture software (Megacybernetics Pro-Express version 4.1 and cool-snap kit).
###end p 24
###begin title 25
Measurement of chemokines
###end title 25
###begin p 26
###xml 71 72 71 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 72 75 72 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
Brain tissue extracts were obtained from control and EAE mice (WT and B2-/-). Brains were removed after intravital microscopy, and the left and right hemispheres were stored on ice. Thereafter, using Ultra-Turrax, each hemisphere was homogenized in extraction solution (100 mg of tissue per 1 mL) containing 0.4 M NaCl, 0.05% Tween 20, 0.5% BSA, 0.1 mM phenylmetilsulfonil fluoride, 0.1 mM benzetonio chloride, 10 mM EDTA and 20 KIU aprotinin. The brain homogenate was spun at 10000 x g for 10 min at 4degreesC and the supernatants were stored at -70degreesC. The concentrations of CCL2, CCL3, CCL5, TNFalpha and IFNgamma were determined in the supernatants of the brain extracts, at a 1:3 dilution in PBS containing 1% BSA, using an ELISA set-up commercially available according to the procedure supplied by the manufacturer (R&D Systems, Minneapolis, MN and Pharmingen, San Diego, CA).
###end p 26
###begin title 27
Statistical analysis
###end title 27
###begin p 28
Data are shown as mean +/- SEM. Significance was assessed using an ANOVA parametric test with Bonferroni correction for multiple comparisons. Statistical significance was set at P < 0.05.
###end p 28
###begin title 29
Results
###end title 29
###begin title 30
Clinical assessment and histopathology
###end title 30
###begin p 31
###xml 12 13 12 13 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 13 17 13 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 45 51 45 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink">35&#8211;55 </sub>
###xml 293 294 293 294 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 294 298 294 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 624 626 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 715 716 711 712 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 716 720 712 716 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 734 736 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 17 21 <span type="species:ncbi:10090">mice</span>
###xml 298 302 <span type="species:ncbi:10090">mice</span>
All WT and B2-/- mice developed EAE after MOG35-55 administration. Clinical symptoms appeared on day 11 post MOG-injection and peaked around day 14 after which were stable through day 18, the last day for animal evaluation. There were no deaths during the course of EAE development. However, B2-/- mice showed a modest but statistically significant reduction (n = 7, mean clinical severity score = 2.4 +/- 0.6) in neurological impairment at the peak of disease (day 14) and during the final plateau phase of disease when compared with their WT group counterparts (n = 7, mean clinical severity score = 3.6 +/- 0.24) (Figure 1A). In addition, there was significant weight loss in EAE WT animals compared to the EAE B2-/- group (Figure 1B).
###end p 31
###begin p 32
###xml 0 27 0 27 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Clinical assessment of EAE.</bold>
###xml 95 96 95 96 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 96 100 96 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 243 244 241 242 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 244 248 242 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
###xml 115 119 <span type="species:ncbi:10090">mice</span>
Clinical assessment of EAE. Clinical signs (n = 7 mice/group) were daily monitored, comparing B2-/- (▼) and WT (■) mice during 18 days after EAE induction (A) and body weight gain or loss (B). Data is expressed as mean +/- SEM. *P < 0.05 for B2-/- versus WT on the peak of disease (day 14 post-induction).
###end p 32
###begin p 33
###xml 95 96 95 96 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 96 100 96 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 588 590 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 611 612 611 612 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 612 616 612 616 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 774 776 774 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 781 783 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2D</xref>
###xml 100 104 <span type="species:ncbi:10090">mice</span>
###xml 153 157 <span type="species:ncbi:10090">mice</span>
Histopathological evaluation of the brain, cerebellum and spinal cord was performed in WT and B2-/- mice at day 14 after EAE induction. Brains of EAE WT mice showed a marked perivascular infiltration of mononuclear cells around pial and cerebral cortex venules (Figure 2A). The inflammatory process extended from the meninges into cerebral cortex parenchyma and was characterized by focal intense mononuclear infiltration. The meninges and white matter of spinal cord of the EAE WT group presented an intense focal inflammatory response associated with white matter vacuolization (Figure 2C). However, the EAE B2-/- group showed only discrete focal inflammatory infiltrates of mononuclear cells, predominantly in association with discrete white matter vacuolization (Figure 2B and 2D).
###end p 33
###begin p 34
###xml 52 53 52 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 53 57 53 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 0 69 0 69 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Histopathological analysis of EAE WT(A, C) and EAE B<sub>2</sub><sup>-/- </sup>mice (B, D).</bold>
###xml 498 499 498 499 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 499 503 499 503 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
###xml 475 479 <span type="species:ncbi:10090">mice</span>
###xml 503 507 <span type="species:ncbi:10090">mice</span>
Histopathological analysis of EAE WT(A, C) and EAE B2-/- mice (B, D). The analysis was performed on H&E-stained sections of brain (A, B) and spinal cord (C, D) at day 14. Observe the marked perivascular infiltration of mononuclear cells in WT brain meninges (A) and the perivascular and inflammatory infiltration of parenchyma (superior and inferior details in A) and spinal cord (C, white arrows). Degenerative changes of white matter are increased in the spinal cord of WT mice in comparison to B2-/- mice (C, black arrows). Original magnification 150x.
###end p 34
###begin title 35
Rolling and adhesion of leukocytes in cerebral microvasculature on day 14
###end title 35
###begin p 36
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 512 514 512 514 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 615 617 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 690 692 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 752 753 752 753 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 753 757 753 757 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 792 794 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 884 885 884 885 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 885 889 885 889 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 677 681 <span type="species:ncbi:10090">mice</span>
###xml 779 783 <span type="species:ncbi:10090">mice</span>
EAE pathogenesis requires migration of activated T cells from peripheral lymphoid tissue to the CNS, which presumably occurs in a multi-step manner. To migrate into sites of inflammation, leukocytes must first tether and roll along the vessel before they firmly adhere and emigrate out of the vasculature. Firm adhesion is triggered by the action of chemoattractant molecules, such as chemokines [26]. EAE induced an increase in leukocyte rolling which presented the same profile in all groups. The deletion of B2 genes did not alter the rolling of leukocytes on pial vessel walls when compared to WT group (Figure 3A). EAE also induced an increase of leukocyte adhesion in WT mice (Figure 3B). On the other hand, leukocyte adhesion was diminished in B2-/- in comparison with WT mice (Figure 3B). In summary, both leukocyte recruitment and histopathological alterations decreased in B2-/- when compared to the EAE WT.
###end p 36
###begin p 37
###xml 0 55 0 55 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Leukocyte-endothelial interactions in pial vasculature.</bold>
###xml 316 319 314 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink">###</sup>
###xml 353 357 <span type="species:ncbi:10090">mice</span>
Leukocyte-endothelial interactions in pial vasculature. Intravital microscopy was used to assess leukocytes rolling (A) and adhesion (B) on day 14 post-immunization. The analysis was performed in 4-5 vessels per animal (n = 6 per group). Results are expressed as mean +/- SEM. ***P < 0.001 when compared to control; ###P < 0.001 when compared to EAE WT mice.
###end p 37
###begin title 38
Chemokine release in the brain
###end title 38
###begin p 39
###xml 136 137 136 137 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 137 141 137 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 250 255 250 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A, B</xref>
###xml 262 263 262 263 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 263 267 263 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 408 409 408 409 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 409 413 409 413 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 478 480 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 584 586 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 685 687 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 237 241 <span type="species:ncbi:10090">mice</span>
###xml 267 271 <span type="species:ncbi:10090">mice</span>
###xml 340 344 <span type="species:ncbi:10090">mice</span>
###xml 413 417 <span type="species:ncbi:10090">mice</span>
###xml 541 545 <span type="species:ncbi:10090">mice</span>
###xml 655 659 <span type="species:ncbi:10090">mice</span>
In order to assess the involvement of kinin receptors in the cerebral chemokine release after EAE induction, brain tissues from WT and B2-/- were examined. EAE induction enhanced cerebral production of the chemokines CCL2 and CCL5 in WT mice (Figure 4A, B). In B2-/- mice, the levels of CCL2 were significantly lower than those found in WT mice (Figure 4A). In addition, the production of CCL5 was lower in B2-/- mice when compared to their WT controls subjected to EAE (Figure 4B). There was no difference in cerebral CCL3 expression in WT mice before or after EAE induction (Figure 4C). Moreover, expression of CCL3 was similar in WT and gene-deficient mice subjected to EAE (Figure 4C).
###end p 39
###begin p 40
###xml 0 69 0 69 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Kinetics of cytokine and chemokine production in the CNS of EAE mice.</bold>
###xml 276 278 268 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink">##</sup>
###xml 64 68 <span type="species:ncbi:10090">mice</span>
Kinetics of cytokine and chemokine production in the CNS of EAE mice. Cerebral levels of CCL2 (A), CCL5 (B), CCL3 (C), TNFalpha (D) and IFNgamma (E) were measured by ELISA (n = 6). Statistically significant differences are indicated by: **P < 0.01 when compared with control; ##P < 0.01 when compared with WT.
###end p 40
###begin p 41
###xml 216 217 208 209 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 217 221 209 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 325 330 309 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4D, E</xref>
###xml 431 432 415 416 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 432 436 416 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 221 225 <span type="species:ncbi:10090">mice</span>
###xml 440 444 <span type="species:ncbi:10090">mice</span>
Considering the important participation of IFNgamma and TNFalpha in T-cell trafficking to CNS, we evaluated the role of kinin receptors on the cerebral production of these pro-inflammatory cytokines. EAE WT and EAE B2-/- mice showed increased TNFalpha and IFNgamma in brain tissue, when compared to the control group (Figure 4D, E). However, no statistical difference was found in the cerebral cytokines levels between WT EAE and B2-/- EAE mice.
###end p 41
###begin title 42
Discussion
###end title 42
###begin p 43
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 422 424 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 425 427 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 460 461 460 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
The kallikrein-kinin system is one of the first inflammatory pathways activated after tissue damage. Particularly because of its ability to increase vascular permeability, the kallikrein-kinin system has been investigated for its ability to promote brain edema and secondary brain damage in various models of central nervous system injuries, for example; bacterial meningitis [28], traumatic brain and spinal cord injury [29-32], and global cerebral ischemia [4]. Although, kinins are known to be released and have several effects in the CNS, their cerebral effects in EAE pathogenesis remain unclear.
###end p 43
###begin p 44
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 385 389 <span type="species:ncbi:10116">rats</span>
It is known that pretreatment with B2 receptor antagonist markedly inhibits inflammatory responses in lungs and intestine [15,33] by suppressing leukocyte recruitment and activation in acute models of inflammation [14,34,35]. In addition, treatment with a B2 receptor antagonist decreases CD44, CD54, CD11a and CD11b expression in various cell types after arthritis induction in Lewis rats [36].
###end p 44
###begin p 45
###xml 269 270 269 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 501 502 501 502 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 502 505 502 505 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 530 535 530 535 <sub xmlns:xlink="http://www.w3.org/1999/xlink">35&#8211;55</sub>
###xml 136 142 <span type="species:ncbi:10090">murine</span>
###xml 507 511 <span type="species:ncbi:10090">mice</span>
This study was designed to provide further insights into the molecular mechanisms of proinflammatory cell trafficking into the CNS in a murine model of EAE. As kinin receptors appear to mediate leukocyte-endothelium interaction induced by certain inflammatory stimuli [4,13], our aim was to determine the putative role of kallikrein-kinin system in the cerebral inflammatory response, via the kinin B2 receptor, after EAE development. For this, we used wild-type (WT) and kinin B2 receptor knockout (B2-/-) mice subjected to a MOG35-55-induced EAE model of multiple sclerosis.
###end p 45
###begin p 46
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 389 391 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 434 436 434 436 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 717 718 717 718 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 718 722 718 722 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 903 904 903 904 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 904 908 904 908 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 935 937 935 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1089 1090 1089 1090 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1090 1094 1090 1094 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1204 1206 1204 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1268 1270 1268 1270 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1411 1412 1411 1412 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1412 1416 1412 1416 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1594 1596 1594 1596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
###xml 246 251 <span type="species:ncbi:9606">human</span>
###xml 408 412 <span type="species:ncbi:10090">mice</span>
###xml 722 726 <span type="species:ncbi:10090">mice</span>
###xml 1094 1098 <span type="species:ncbi:10090">mice</span>
###xml 1416 1420 <span type="species:ncbi:10090">mice</span>
The MOG peptide can induce typical EAE disease in C57BL/6 mice and in other strains. MOG, which represents only ~0.05% of myelin proteins, elicits a major antibody response that has been correlated with disease severity and demyelination in both human and animal models of MS [37,38]. There is some evidence for activation of the kallikrein-kinin system during inflammation in this model [39]. In our hands, mice that lack the kinin B2 receptor and are subjected to EAE had a statistically significant reduction in neurological impairment at the peak of disease (day 14) and during the final plateau phase of disease, when compared with the WT EAE group. Our results also reveal lesser degrees of weight loss in EAE B2-/- mice when compared to WT EAE animals. These findings are consistent with a previous study that showed prolonged survival, improved motor function, and smaller cerebral infarcts in B2-/- after experimental stroke [40]. However, leukocyte recruitment was not investigated in this study. On the other hand, our findings of improvement of neurological clinical score in B2-/- mice associated with impaired leukocyte recruitment parameters are in contrast to the findings of Xia et al. [41], which provide evidence for a protective role of the kinin B2 receptor against ischemic stroke. In the latter study, the authors also found increased neutrophil accumulation in infarcted brain areas in B2-/- mice. Recently these results have been consistently contested, leading to the conclusion that the deficiency of bradykinin receptor B2 is not detrimental in experimental stroke [42], and may be beneficial in other pathological conditions.
###end p 46
###begin p 47
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 393 394 393 394 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 394 398 394 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 240 244 <span type="species:ncbi:10090">mice</span>
###xml 398 402 <span type="species:ncbi:10090">mice</span>
EAE pathogenesis requires the infiltration of leukocytes into brain parenchyma. In a previous study undertaken by our group, we showed that there are increased leukocyte-endothelial cell interactions (rolling and adhesion) in brains of EAE mice, as assessed by cerebral intravital microscopy [18]. In the present series of experiments, leukocyte adherence, but not rolling, was suppressed in B2-/- mice submitted to the EAE protocol.
###end p 47
###begin p 48
###xml 170 171 170 171 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 171 175 171 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 426 427 426 427 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 427 431 427 431 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 521 523 521 523 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 175 179 <span type="species:ncbi:10090">mice</span>
###xml 267 271 <span type="species:ncbi:10090">mice</span>
###xml 431 435 <span type="species:ncbi:10090">mice</span>
The latter findings were corroborated by histopathological examination of brain sections, which showed inhibition of mononuclear cell influx and inflammatory lesions on B2-/- mice after EAE induction. In addition, histopathological analysis of spinal cord for EAE WT mice showed a marked inflammatory response with intense vacuolization in white matter, contrasting with very discrete infiltrates and degenerative changes in B2-/- mice after EAE induction. Thus, the present study clearly suggests an important role for B2 in mediating leukocyte adherence to vessels in brain, and extensively in spinal cord, as suggested by histology of both sites in the same animal.
###end p 48
###begin p 49
###xml 198 199 198 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 254 256 254 256 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 335 337 335 337 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 439 441 439 441 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 488 490 488 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 543 545 543 545 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 722 724 722 724 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 729 731 729 731 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 788 790 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 846 848 846 848 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 931 933 931 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 934 936 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 477 480 <span type="species:ncbi:10116">rat</span>
###xml 782 786 <span type="species:ncbi:10090">mice</span>
###xml 890 900 <span type="species:ncbi:10141">guinea pig</span>
###xml 905 910 <span type="species:ncbi:9940">sheep</span>
These suggestions draw support from described patterns of kinin receptor distribution in the CNS. High-density kinin binding sites have been identified in the CNS, mainly in cerebral blood vessels [2]. Previous studies have demonstrated the presence of B1 receptor in the brain and spinal cord in different species [43]. In addition, B2 receptors have been localized in experimental brain tumors [44]. Chen et al have also shown that the B2 receptor is widely expressed within rat brain [45]. In contrast to available knowledge on bradykinin B2 receptors in brain, the distribution of these receoptors in spinal cord and the potential functional roles in spinal cord remain unclear. RT-PCR studies reveal the presence of B1 and B2 receptor mRNA in neurons of dorsal root ganglia in mice [46]. Murone et al. have demonstrated the distribution of B2 receptors in the brain and spinal cord of guinea pig and sheep by autoradiography [47,48]. Further studies using intravital microscopy of spinal cord vessels are necessary in order to define functional roles of these receptors in pathological conditions.
###end p 49
###begin p 50
###xml 170 172 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 194 196 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 197 199 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 225 227 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 584 586 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 669 670 666 667 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 670 674 667 671 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 795 796 792 793 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 796 800 793 797 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 578 582 <span type="species:ncbi:10090">mice</span>
###xml 674 678 <span type="species:ncbi:10090">mice</span>
###xml 800 804 <span type="species:ncbi:10090">mice</span>
Activation of kinin receptors may underlie production of chemokines in several models of inflammation, including response to the cytokine IL-1beta in mesenteric venules [49], inflammatory pain [50,51], and allergic rhinitis [21]. Considering previous data, it may be possible that kinin receptors could be regulating the expression of chemokines and, consequently, leukocyte trafficking after EAE induction. Our previous studies showed that the chemokines CCL2 and CCL5, but not CCL3, are involved in the adherence, but not rolling, of leukocytes in the microvasculature of EAE mice [18]. In this study we demonstrate that CCL5 expression is greatly suppressed in EAE B2-/- mice, when compared to EAE WT. These findings could partially explain the inhibition of leukocyte adherence observed in B2-/- mice, as a probable consequence of decreased levels of CCL5.
###end p 50
###begin p 51
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 280 285 280 285 <sub xmlns:xlink="http://www.w3.org/1999/xlink">35&#8211;55</sub>
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 419 421 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 519 521 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 579 580 579 580 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 580 584 580 584 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 796 798 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 877 878 877 878 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 878 882 878 882 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 189 197 <span type="species:ncbi:9606">patients</span>
###xml 301 305 <span type="species:ncbi:10090">mice</span>
###xml 507 513 <span type="species:ncbi:10090">murine</span>
###xml 584 588 <span type="species:ncbi:10090">mice</span>
###xml 600 604 <span type="species:ncbi:10090">mice</span>
###xml 882 886 <span type="species:ncbi:10090">mice</span>
The chemokine CCL2 and its receptors CCR2 are thought to play an important role in the pathogenesis of EAE in several conditions. For example, both CCL2 and CCR2 are expressed in brains of patients with MS [52,53] and deletion of CCR2 leads to an almost complete inhibition of MOG35-55-induced EAE in mice [16]. Blocking of the CCL2-CCR2 axis with neutralizing antibodies limits the development of subsequent relapses [54]. Our previous studies have also shown a role for CCL2 in leukocyte adherence during murine EAE [18]. In the present experiments, CCL2 levels were lower in B2-/- mice than in WT mice after EAE induction. Previous studies have shown that CCL2 may be critical not only for leukocyte recruitment but also for the activation of T cells during inflammatory and immune responses [53,55]. Thus, it is possible that the inhibition of CCL2 production observed in B2-/- mice would lead to lesser activation of infiltrated leucocytes and, hence, stabilization of the severity of clinical signs.
###end p 51
###begin p 52
###xml 278 280 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 281 283 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 324 326 312 314 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 455 456 439 440 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 456 460 440 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 562 563 542 543 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 563 567 543 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 605 607 585 587 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 732 734 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 759 761 735 737 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 889 891 861 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 1018 1020 990 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 460 464 <span type="species:ncbi:10090">mice</span>
###xml 587 591 <span type="species:ncbi:10090">mice</span>
###xml 969 973 <span type="species:ncbi:10116">rats</span>
There are many studies supporting the clinical involvement of TNF-alpha in EAE. Elevated expression of TNF-alpha can be found in the CNS during acute episodes of disease, and blockage of TNF-alpha with neutralizing antibodies and soluble receptors will ameliorate signs of EAE [56,57]. In order to evaluate the role of the B2 receptor in cerebral TNF-alpha expression after EAE induction, brain tissue extracts were obtained from control, WT EAE and EAE B2-/- mice. We found a significant increase in TNF-alpha levels at day 14 (peak of disease) in both WT and B2-/- compared to control mice. Absence of B2 receptor did not modulate TNF-alpha expression after EAE induction. These results are consistent with those of Cunha et al. [58] who demonstrated that B2 kinin receptor antagonist, at a dose that inhibits carrageenin-induced hypernociception, does not inhibit release of TNF-alpha [54]. Direct, bradykinin-independent, release of cytokines was also suggested in rats after administration of large doses of LPS [59].
###end p 52
###begin p 53
###xml 1 3 1 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 31 33 31 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 95 97 95 97 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 115 117 115 117 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 199 201 199 201 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 329 330 329 330 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 351 353 351 353 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 535 537 535 537 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 652 654 652 654 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 903 905 903 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 906 908 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 1080 1082 1080 1082 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 430 434 <span type="species:ncbi:10090">mice</span>
###xml 685 689 <span type="species:ncbi:10090">mice</span>
B2 is partially necessary for B1 receptor induction as supported by the consistent finding of B2 participation in B1 mRNA and protein induction in several models of inflammation [60]. The expressed B1 is relevant to the control of CCL5 production and to ensuing leukocyte adherence and tissue inflammation. In addition to these B1-dependent effects, B2 receptor activation is necessary for the production of CCL2 in brains of EAE mice. Previous studies using rodent models of traumatic brain injury have corroborated the finding that B2 receptor is present and involved in cerebral alterations [61,62]. Our study clearly demonstrates that blockade of B2 receptors is beneficial in EAE mice in reducing inflammatory events such as leukocyte adhesion and activation. We should note, however, that various studies have demonstrated an important role for adhesion molecules in both EAE and MS pathogenesis [63-66] and, at this time, we can not yet exclude the possibility that there is altered expression of adhesion molecules such as ICAM-1 and VCAM-1 on brain endothelial cells of B2 deficient animals.
###end p 53
###begin title 54
Conclusion
###end title 54
###begin p 55
###xml 190 192 190 192 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 363 364 363 364 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Our study proposes an important and previously unappreciated involvement of the kallikrein-kinin system in the pathogenesis of EAE. In summary, our results clearly show a definite role for B2 receptors in mediating leukocyte adherence, chemokine production and clinical disease outcome. Altogether, our data indicate that blockade of kinin receptors, especially B2, may represent an additional and novel therapeutic strategy for the treatment of MS.
###end p 55
###begin title 56
List of abbreviations
###end title 56
###begin p 57
###xml 50 56 <span type="species:ncbi:9913">bovine</span>
###xml 73 76 <span type="species:ncbi:31658">CFA</span>
ANOVA: analysis of variance; BK: bradykinin; BSA: bovine serum albumine; CFA: complete Freund adjuvant; CNS: central nervous system; CCL: chemokine ligand; CCR: chemokine receptor; ELISA: enzyme linked immunosorbent assay; ICAM: intercellular adhesion molecule; IFNgamma: interferon gama; IL-1beta: interleukin-1beta; MCAO: middle cerebral artery occlusion; MOG: myelin oligodendrocyte glycoprotein; MS: multiple sclerosis; PBS: phosphate buffer sodium; SEM: standard error mean; TNFalpha: tumor necrosis factor alpha; VCAM: vascular cell adhesion molecule; WT: wild type.
###end p 57
###begin title 58
Competing interests
###end title 58
###begin p 59
The authors declare that they have no competing interests.
###end p 59
###begin title 60
Authors' contributions
###end title 60
###begin p 61
###xml 310 311 310 311 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 311 315 311 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
ACS, MMT and JCT conceived the study, and wrote the manuscript. ACS carried out the experiments and analyzed the results, with the following exceptions: LJ synthetize the peptide MOG. ER extracted RNA samples and prepared cDNA from the brain. RMEA helped in the histological studies. JBP, JLP and MB provided B2-/- animals. All authors read and approved the final manuscript.
###end p 61
###begin title 62
Acknowledgements
###end title 62
###begin p 63
We are grateful to Valdineria Borges and Vania Aparecida N. Silva for expert technical and clerical assistance. This work received financial support from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil) and Fundacao do Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG, Brazil). MMT, JBP, JLP, LJ and RMEA are supported by research fellowship from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq). The authors kindly thank Dr Christopher Kushmerick for carefully reading this manuscript.
###end p 63
###begin article-title 64
Brain kallikrein-kinin system: from receptors to neuronal pathways and physiological functions
###end article-title 64
###begin article-title 65
Kinin receptors in pain and inflammation
###end article-title 65
###begin article-title 66
B1 receptors as a new target. Could this B the 1?
###end article-title 66
###begin article-title 67
Bradykinin antagonists reduce leukocyte endothelium interactions after global cerebral ischemia
###end article-title 67
###begin article-title 68
Bradykinin B1 receptor expression and function on T lymphocytes in acute multiple sclerosis
###end article-title 68
###begin article-title 69
###xml 45 49 <span type="species:ncbi:10090">mice</span>
The use of kinin B1 and B2 receptor knockout mice and selective antagonists to characterize the nociceptive responses caused by kinins at spinal level
###end article-title 69
###begin article-title 70
###xml 28 31 <span type="species:ncbi:10116">rat</span>
Kinin receptors in cultured rat microglia
###end article-title 70
###begin article-title 71
The B1 receptors for kinins
###end article-title 71
###begin article-title 72
Molecular pathogenesis of neuroinflammation
###end article-title 72
###begin article-title 73
Immune regulation and CNS autoimmune disease
###end article-title 73
###begin article-title 74
Kinins in pain and inflammation
###end article-title 74
###begin article-title 75
Angiotensin II and bradykinin regulate the expression of P-selectin on the surface of endothelial cells in culture
###end article-title 75
###begin article-title 76
###xml 84 89 <span type="species:ncbi:10090">mouse</span>
Association between kinin B(1) receptor expression and leukocyte trafficking across mouse mesenteric postcapillary venules
###end article-title 76
###begin article-title 77
###xml 111 122 <span type="species:ncbi:10141">guinea pigs</span>
Involvement of bradykinin B1 and B2 receptors in pulmonary leykocyte accumulation induced by Sephadex beads in guinea pigs
###end article-title 77
###begin article-title 78
Role of bradykinin B2 and B1 receptors in the local, remote, and systemic inflammatory responses that follow intestinal ischemia and reperfusion injury
###end article-title 78
###begin article-title 79
###xml 59 63 <span type="species:ncbi:10090">mice</span>
Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2
###end article-title 79
###begin article-title 80
Antibody targeting of the CC chemokine ligand 5 results in diminished leukocyte infiltration into the central nervous system and reduced neurologic disease in a viral model of multiple sclerosis
###end article-title 80
###begin article-title 81
CCL2 and CCL5 mediate leukocyte adhesion in experimental autoimmune encephalomyelitis - an intravital microscopy study
###end article-title 81
###begin article-title 82
Role of mitogen-activated protein kinases in the expression of the B1 kinin receptors induced by tissue injury
###end article-title 82
###begin article-title 83
Bradykinin stimulates type II alveolar cells to release neutrophil and monocyte chemotactic activity and inflammatory cytokines
###end article-title 83
###begin article-title 84
###xml 90 98 <span type="species:ncbi:9606">patients</span>
Bradykinin increases the in vivo expression of CXC chemokine receptors CXCR1 and CXCR2 in patients with allergic rhinitis
###end article-title 84
###begin article-title 85
In vivo B1 kinin-receptor up-regulation. Evidence for involvement of protein kinases and nuclear factor kappa B pathways
###end article-title 85
###begin article-title 86
###xml 154 159 <span type="species:ncbi:9606">human</span>
Bradykinin B1 receptor up-regulation by interleukin-1beta and B1 agonist occurs through independent and synergistic intracellular signaling mechanisms in human lung fibroblasts
###end article-title 86
###begin article-title 87
###xml 50 54 <span type="species:ncbi:10090">mice</span>
Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors
###end article-title 87
###begin article-title 88
Bradykinin antagonists: discovery and development
###end article-title 88
###begin article-title 89
Overlapping roles of P-selectin and alpha 4-integrin to recruit leukocytes to the central nervous system in experimental autoimmune encephalomyelitis
###end article-title 89
###begin article-title 90
A role for platelets and endothelial selectin in tumor necrosis factor-induced leukocyte recruitment in the brain microvasculature
###end article-title 90
###begin article-title 91
###xml 102 105 <span type="species:ncbi:10116">rat</span>
Effect of the bradykinin B2 receptor antagonist Hoe140 in experimental pneumococcal meningitis in the rat
###end article-title 91
###begin article-title 92
###xml 147 151 <span type="species:ncbi:10116">rats</span>
Significant reduction in brain swelling by administration of nonpeptide kinin B2 receptor antagonisy LF 160687Ms after controlled impact injury in rats
###end article-title 92
###begin article-title 93
Bradykinin B2, but not B1, receptor antagonist has a neuroprotective effect after brain injury
###end article-title 93
###begin article-title 94
###xml 154 158 <span type="species:ncbi:10116">rats</span>
LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces brain edema and improves long-term neurological function recovery after closed head trauma in rats
###end article-title 94
###begin article-title 95
###xml 48 54 <span type="species:ncbi:10090">murine</span>
Detrimental role of bradykinin B2 receptor in a murine model of diffuse brain injury
###end article-title 95
###begin article-title 96
Role of the bradykinin B2 receptor for the local and systemic inflammatory response that follows severe reperfusion injury
###end article-title 96
###begin article-title 97
###xml 99 104 <span type="species:ncbi:9940">sheep</span>
A bradykinin antagonist modifies allergen-induced mediator release and late bronchial responses in sheep
###end article-title 97
###begin article-title 98
###xml 135 139 <span type="species:ncbi:10116">rats</span>
Suppressive effect of distinct bradykinin B2 receptor antagonist on allergen-evoked exudation and leukocyte infiltration in sensitized rats
###end article-title 98
###begin article-title 99
Interactions between bradykinin (BK) and cell adhesion molecule (CAM) expression in peptidoglycan-polysaccharide (PG-PS)-induced arthritis
###end article-title 99
###begin article-title 100
Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis
###end article-title 100
###begin article-title 101
Identification of autoantibodies associated with myelin damage in multiple sclerosis
###end article-title 101
###begin article-title 102
Increased blood concentration of des-Arg9-bradykinin in experimental allergic encephalomyelitis
###end article-title 102
###begin article-title 103
###xml 151 155 <span type="species:ncbi:10090">mice</span>
Release of bradykinin and expression of kinin B2 receptor in the brain: Role for cell death and brain edema formation after local cerebral ischemia in mice
###end article-title 103
###begin article-title 104
###xml 43 47 <span type="species:ncbi:10090">mice</span>
Postischemic brain injry is exacerbated in mice lacking the kinin B2 receptor
###end article-title 104
###begin article-title 105
Deficiency of bradykinin receptor B2 is not detrimental in experimental stroke
###end article-title 105
###begin article-title 106
Localization of B1 bradykinin receptor mRNA in the primate brain and spinal cord: an in situ hybridization study
###end article-title 106
###begin article-title 107
Correlation between bradykinin-induced blood-tumor barrier permeability and B2 receptor expresion in experimental braintumors
###end article-title 107
###begin article-title 108
###xml 43 46 <span type="species:ncbi:10116">rat</span>
B2 bradykinin receptor immunoreactivity in rat brain
###end article-title 108
###begin article-title 109
###xml 54 59 <span type="species:ncbi:10090">mouse</span>
Modulation of long-term potentiation in CA1 region of mouse hippocampal brain slices by GABAA receptor benzodiazepine site ligands
###end article-title 109
###begin article-title 110
###xml 68 78 <span type="species:ncbi:10141">guinea-pig</span>
Characterization and localization of bradykinin b2 receptors in the guinea-pig using a radioiodinated Hoe140 analogue
###end article-title 110
###begin article-title 111
###xml 43 48 <span type="species:ncbi:9940">sheep</span>
Distribution of bradykinin b2 receptors in sheep brain and spinal cords visualized by in vitro autoradiograph
###end article-title 111
###begin article-title 112
A novel inflammatory pathway involved in leukocyte recruitment: role for the kinin B1 receptor and the chemokine CXCL5
###end article-title 112
###begin article-title 113
Bradykinin B1 and B2 receptors, tumour necrosis factor alpha and inflammatory hyperalgesia
###end article-title 113
###begin article-title 114
###xml 76 80 <span type="species:ncbi:10090">mice</span>
A cascade of cytokines mediates mechanical inflammatory hypernociception in mice
###end article-title 114
###begin article-title 115
###xml 110 118 <span type="species:ncbi:9606">patients</span>
Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients
###end article-title 115
###begin article-title 116
The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE)
###end article-title 116
###begin article-title 117
Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1 alpha and monocyte chemotactic protein-1
###end article-title 117
###begin article-title 118
Control of Th2 polarization by chemokine monocyte chemoattractant protein-1
###end article-title 118
###begin article-title 119
An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis
###end article-title 119
###begin article-title 120
Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system
###end article-title 120
###begin article-title 121
###xml 64 68 <span type="species:ncbi:10090">mice</span>
TNF-alpha and IL-1beta mediate inflammatory hypernociception in mice triggered by B1 but not B2 kinin receptor
###end article-title 121
###begin article-title 122
Bradykinin initiates cytokine mediated inflammatory hyperalgesia
###end article-title 122
###begin article-title 123
Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes
###end article-title 123
###begin article-title 124
Pharmacological profile of LF 16-0687 Ms, a new potent non-peptide bradykinin B2 receptor antagonist
###end article-title 124
###begin article-title 125
###xml 87 93 <span type="species:ncbi:10090">murine</span>
LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces ischemic brain injury in a murine model of transient focal cerebral ischemia
###end article-title 125
###begin article-title 126
Cell surface adhesion molecules and cytokine profiles in primary progressive multiple sclerosis
###end article-title 126
###begin article-title 127
Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS
###end article-title 127
###begin article-title 128
Intercellular adhesion molecule-1 expression is required on multiple cell types for the development of experimental autoimmune encephalomyelitis
###end article-title 128
###begin article-title 129
Lipoic acid inhibits expression of ICAM-1 and VCAM-1 by CNS endothelial cells and T cell migration into the spinal cord in experimental autoimmune encephalomyelitis
###end article-title 129

